Hepatitis B Topics HBV Populations Children & Adolescents
Updated Entecavir Label Expands Indication for Children with Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 25 March 2014 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved new label information for entecavir (Baraclude), a nucleoside analog used to treat chronic hepatitis B virus (HBV) infection. The revised label expands the indication for pediatric use by children age 2 years and up.
Teens Vaccinated Against Hepatitis B as Infants May Lose Immunity
- Details
- Category: HBV Prevention
- Published on Friday, 11 January 2013 00:00
- Written by NIH
Adolescents who received combined active-passive hepatitis B virus (HBV) immunization soon after birth may lose "immunological memory" that protects them from future infection, with the HBeAg status of the mother playing a key role, researchers reported in the January 2013 issue of Hepatology.
Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 02 October 2012 00:00
- Written by Liz Highleyman
Tenofovir (Viread) continues to be effective for treating chronic hepatitis B patients who have developed resistance to the related drug adefovir (Hepsera), according to a report in the August 14, 2012, online edition of Antiviral Therapy.
Entecavir Alone Works as Well as Combo for First-time Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Treating chronic hepatitis B with entecavir (Baraclude) alone worked as well as dual therapy using entecavir plus tenofovir (Viread) for patients starting treatment for the first time, according to a study described in the September 2012 issue of Gastroenterology.
Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B
- Details
- Category: Approved HBV Drugs
- Published on Friday, 28 September 2012 00:00
- Written by Liz Highleyman
While obese chronic hepatitis B patients and heavy drinkers did not have impaired virological response to entecavir (Baraclude), alcohol use did reduce the likelihood of alanine aminotransferase (ALT) normalization, according to study findings reported in the June 2012 issue of Clinical and Molecular Hepatology. 
Web Design and Development by